Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 
Leora  Horn

Leora Horn, M.D., M.Sc.

Associate Professor of Medicine (Hematology and Oncology)
Assistant Director, Educator Development Program
Clinical Director, Thoracic Oncology Program
Medical Oncologist

  • Appointments
    615-936-8422
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Henry-Joyce Cancer Clinic
    (615) 936-8422 or 1 (877) 936-8422

    Office
    615-936-3524
  • Faxes
    Henry-Joyce Cancer Clinic Fax
    (615) 343-8668
    Office Fax
    615-343-7602
  • Addresses
    Henry-Joyce Cancer Clinic
    1301 Medical Center Drive, Suite 1710
    Nashville, Tennessee 37232-7415
    Website

    Office
    2220 Pierce Avenue
    777 Preston Research Building
    Nashville, TN 37232-6307
Profile

Dr. Horn received her Honors Bachelor of Science and Masters of Science in Pharmacology from the University of Toronto where she also attended medical school and trained in internal medicine and medical oncology. She completed a sub-specialty fellowship in Thoracic Oncology at Vanderbilt University.
Read more...

Dr. Horn received her Honors Bachelor of Science and Masters of Science in Pharmacology from the University of Toronto where she also attended medical school and trained in internal medicine and medical oncology. She completed a sub-specialty fellowship in Thoracic Oncology at Vanderbilt University. Her fellowship was funded by an award from the Canadian Association of Medical Oncology.  Dr. Horn is an Assistant Professor of Medicine in the Division of Hematology/Oncology.

Dr Horn's clinical practice focuses primarily on the care of patients with lung cancer. She is the Clinical Director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center.  Her research interests include experimental therapeutics and medical education. Her work was recently recognized with a VICC Impact award for her research contributions made to the Cancer Center.

Dr. Horn is currently completing a Masters in Health Professional Education through the University of Illinois Chicago and has a cross appointment to the Office of Teaching and Learning in Medicine where she is the Assistant Director of the Educator Development Program (EDP) at Vanderbilt.

Dr. Horn is Principal Investigator on several lung cancer clinical trials and educational projects. She has published over 30 papers and book chapters including original papers, reviews and the recent chapter on "neoplasms of the Lung" in Harrison's Principles of Internal Medicine, 18th edition. She is an active member in the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the Royal College of Physicians and Surgeons of Canada.

Education
 
  • 1992-1996 Honours Bachelor of Science with High Distinction Pharmacology, University of Toronto
  • 1996-1998 Masters of Science Pharmacology, University of Toronto
  • 1998-2002 Doctor of Medicine with Honours University of Toronto
  • 2002-2005 Postgraduate training Internal MedicineUniversity of Toronto
  • 2005-2008 Postgraduate training Medical OncologyUniversity of Toronto
  • 2008-2009 Thoracic Oncology FellowVanderbilt University
  • 2008-present Masters in Health Professional EducationUniversity of Illinois
Publications
  • Hames ML, Chen H, Iams W, Aston J, Lovly CM, Horn L. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer¿. Lung Cancer [print-electronic]. 2016 Feb; 92: 29-34. PMID: 26775593, PII: S0169-5002(15)30100-8, DOI: 10.1016/j.lungcan.2015.11.004, ISSN: 1872-8332.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26775593.
  • Karlovich CA, Goldman J, Sun JM, Mann E, Sequist LV, Konopa K, Wen W, Angenendt P, Horn L, Spigel DR, Soria JC, Solomon B, Camidge DR, Gadgeel SM, Paweletz CP, Wu L, Chien S, O'Donnell P, Matheny S, Despain D, Rolfe L, Raponi M, Allen AR, Park K, Wakelee HA. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase 1 study of rociletinib (CO-1686). Clin. Cancer Res [print-electronic]. 2016 Jan 1/8/2016; PMID: 26747242, PII: 1078-0432.CCR-15-1260, DOI: 10.1158/1078-0432.CCR-15-1260, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26747242.
  • Kroop SF, Chung CP, Davidson MA, Horn L, Damp JB, Dewey C. Rheumatologic skills development: what are the needs of internal medicine residents?. Clin. Rheumatol [print-electronic]. 2015 Dec 12/23/2015; PMID: 26694057, PII: 10.1007/s10067-015-3150-4, DOI: 10.1007/s10067-015-3150-4, ISSN: 1434-9949.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26694057.
  • Castellanos EH, Chen SC, Drexler H, Horn L. Making the Grade: The Impact of Low-Grade Toxicities on Patient Preference for Treatment With Novel Agents. J Natl Compr Canc Netw. 2015 Dec; 13(12): 1490-5. PMID: 26656518, PII: 13/12/1490, ISSN: 1540-1413.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26656518.
  • Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med [print-electronic]. 2015 Oct 10/22/2015; 373(17): 1627-39. PMID: 26412456, DOI: 10.1056/NEJMoa1507643, ISSN: 1533-4406.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26412456.
  • Castellanos EH, Horn L. Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress. Curr Treat Options Oncol. 2015 Oct; 16(10): 51. PMID: 26364032, PII: 10.1007/s11864-015-0365-1, DOI: 10.1007/s11864-015-0365-1, ISSN: 1534-6277.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26364032.
  • , Dewey CM, Turner TL, Perkowski L, Bailey J, Gruppen LD, Riddle J, Singhal G, Mullan P, Poznanski A, Pillow T, Robins LS, Rougas SC, Horn L, Ghulyan MV, Simpson D. Twelve tips for developing, implementing, and sustaining medical education fellowship programs: Building on new trends and solid foundations. Med Teach [print-electronic]. 2015 Sep 9/23/2015; 1-9. PMID: 26398270, DOI: 10.3109/0142159X.2015.1056518, ISSN: 1466-187X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26398270.
  • Castellanos EH, Rivera G, Wakelee H, Horn L. Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor--Mutated Non--Small-Cell Lung Cancer With T790M Mutations. Clin Lung Cancer [print-electronic]. 2015 Sep; 16(5): e97-9. PMID: 25842367, PII: S1525-7304(15)00058-3, DOI: 10.1016/j.cllc.2015.02.005, ISSN: 1938-0690.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25842367.
  • Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol [print-electronic]. 2015 Jun 6/20/2015; 33(18): 2004-12. PMID: 25897158, PMCID: PMC4672027, PII: JCO.2014.58.3708, DOI: 10.1200/JCO.2014.58.3708, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25897158.
  • Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M, . Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw. 2015 May; 13(5): 515-24. PMID: 25964637, PII: 13/5/515.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25964637.
  • Horn L. Targeted/emerging therapies for metastatic non-small cell lung cancer. J Natl Compr Canc Netw. 2015 May; 13(5 Suppl): 676-8. PMID: 25995428, PII: 13/5S/676, ISSN: 1540-1413.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25995428.
  • Lammers PE, Lu B, Horn L, Shyr Y, Keedy V. Nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer. Oncologist [print-electronic]. 2015 May; 20(5): 491-2. PMID: 25845992, PMCID: PMC4425395, PII: theoncologist.2015-0030, DOI: 10.1634/theoncologist.2015-0030, ISSN: 1549-490X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25845992.
  • Shyr Y, Horn L, Berry L. Are We Making Progress in Lung Cancer Using Progression-Free Survival as a Surrogate End Point?. JAMA Oncol. 2015 May; 1(2): 202-3. PMID: 26181024, PII: 2196177, DOI: 10.1001/jamaoncol.2015.0407, ISSN: 2374-2445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26181024.
  • Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 2015 Apr 4/30/2015; 372(18): 1689-99. PMID: 25923549, DOI: 10.1056/NEJMoa1411817, ISSN: 1533-4406.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25923549.
  • Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol [print-electronic]. 2015 Mar; 16(3): 257-65. PMID: 25704439, PII: S1470-2045(15)70054-9, DOI: 10.1016/S1470-2045(15)70054-9, ISSN: 1474-5488.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25704439.
  • Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol. 2015 Mar; 10(3): 431-7. PMID: 25415430, PMCID: PMC4479120, DOI: 10.1097/JTO.0000000000000432, ISSN: 1556-1380.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25415430.
  • Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1): S1-63. PMID: 25535693, PMCID: PMC4346098, PII: 01243894-201501001-00001, DOI: 10.1097/JTO.0000000000000405, ISSN: 1556-1380.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25535693.
  • Gilbert J, Chew H, Dewey C, Horn L. Medical education: perils and progress in educating and assessing a new generation of learners. Am Soc Clin Oncol Educ Book. 2015; 33-9. PMID: 25993139, PII: 00115000033, DOI: 10.14694/EdBook_AM.2015.35.33, ISSN: 1548-8756.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25993139.
  • Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol. 2014 Dec; 15(4): 658-69. PMID: 25096781, PMCID: PMC4216599, DOI: 10.1007/s11864-014-0305-5, ISSN: 1534-6277.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25096781.
  • Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 11/27/2014; 515(7528): 563-7. PMID: 25428504, PII: nature14011, DOI: 10.1038/nature14011, ISSN: 1476-4687.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25428504.
  • Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA, Pao W. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov [print-electronic]. 2014 Sep; 4(9): 1036-45. PMID: 25074459, PMCID: PMC4155006, PII: 2159-8290.CD-14-0326, DOI: 10.1158/2159-8290.CD-14-0326, ISSN: 2159-8290.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25074459.
  • Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretic L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat. Med [print-electronic]. 2014 Sep; 20(9): 1027-34. PMID: 25173427, PMCID: PMC4159407, PII: nm.3667, DOI: 10.1038/nm.3667, ISSN: 1546-170X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25173427.
  • Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24797823.
  • Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Rep [print-electronic]. 2014 May 5/22/2014; 7(4): 999-1008. PMID: 24813888, PMCID: PMC4074596, PII: S2211-1247(14)00301-5, DOI: 10.1016/j.celrep.2014.04.014, ISSN: 2211-1247.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24813888.
  • Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin. Cancer Res [print-electronic]. 2014 May 5/1/2014; 20(9): 2264-75. PMID: 24599935, PMCID: PMC4008689, PII: 1078-0432.CCR-13-1591, DOI: 10.1158/1078-0432.CCR-13-1591, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24599935.
  • Horn L. Advances in the treatment of non-small cell lung cancer [editorial]. J Natl Compr Canc Netw. 2014 May; 12(5 Suppl): 764-7. PMID: 24853212, PII: 12/5S/764, ISSN: 1540-1413.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24853212.
  • Shanafelt TD, Raymond M, Kosty M, Satele D, Horn L, Pippen J, Chu Q, Chew H, Clark WB, Hanley AE, Sloan J, Gradishar WJ. Satisfaction with work-life balance and the career and retirement plans of US oncologists. J. Clin. Oncol [print-electronic]. 2014 Apr 4/10/2014; 32(11): 1127-35. PMID: 24616305, PII: JCO.2013.53.4560, DOI: 10.1200/JCO.2013.53.4560, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24616305.
  • Lammers PE, Shyr Y, Li CI, Hutchison AS, Sandler A, Carbone DP, Johnson DH, Keedy VL, Horn L. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J Thorac Oncol. 2014 Apr; 9(4): 559-62. PMID: 24736081, PMCID: PMC3990869, PII: 01243894-201404000-00024, DOI: 10.1097/JTO.0000000000000079, ISSN: 1556-1380.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24736081.
  • Shanafelt TD, Gradishar WJ, Kosty M, Satele D, Chew H, Horn L, Clark B, Hanley AE, Chu Q, Pippen J, Sloan J, Raymond M. Burnout and career satisfaction among US oncologists. J. Clin. Oncol [print-electronic]. 2014 Mar 3/1/2014; 32(7): 678-86. PMID: 24470006, PMCID: PMC3927737, PII: JCO.2013.51.8480, DOI: 10.1200/JCO.2013.51.8480, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24470006.
  • Gregg JR, Horn L, Davidson MA, Gilbert J. Patient enrollment onto clinical trials: the role of physician knowledge. J Cancer Educ. 2014 Mar; 29(1): 74-9. PMID: 24163050, DOI: 10.1007/s13187-013-0548-z, ISSN: 1543-0154.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24163050.
  • Horn L, Carbone DP. Reducing lung cancer mortality: 2014 update [editorial]. Semin. Oncol [print-electronic]. 2014 Feb; 41(1): 3-4. PMID: 24565576, PII: S0093-7754(13)00214-5, DOI: 10.1053/j.seminoncol.2013.12.004, ISSN: 1532-8708.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24565576.
  • Lammers PE, Lovly CM, Horn L. A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. J Natl Compr Canc Netw. 2014 Jan; 12(1): 6-11; quiz 11. PMID: 24453288, PMCID: PMC4151469, PII: 12/1/6, ISSN: 1540-1413.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24453288.
  • Hamann HA, Lee JW, Schiller JH, Horn L, Wagner LI, Chang VT, Fisch MJ. Clinician perceptions of care difficulty, quality of life, and symptom reports for lung cancer patients: an analysis from the Symptom Outcomes and Practice patterns (SOAPP) study. J Thorac Oncol. 2013 Dec; 8(12): 1474-83. PMID: 24189514, PMCID: PMC3936653, DOI: 10.1097/01.JTO.0000437501.83763.5d, ISSN: 1556-1380.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24189514.
  • Lammers PE, Horn L. Targeting angiogenesis in advanced non-small cell lung cancer. J Natl Compr Canc Netw. 2013 Oct 10/1/2013; 11(10): 1235-47. PMID: 24142825, PII: 11/10/1235, ISSN: 1540-1413.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24142825.
  • Yeh P, Chen H, Andrews J, Naser R, Pao W, Horn L. DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clin. Cancer Res [print-electronic]. 2013 Apr 4/1/2013; 19(7): 1894-901. PMID: 23344264, PMCID: PMC4121886, PII: 1078-0432.CCR-12-1894, DOI: 10.1158/1078-0432.CCR-12-1894, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23344264.
  • Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, Sosman JA. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol. 2013 Mar; 200(3): 475-83. PMID: 23436834, PMCID: PMC3652983, PII: 200/3/475, DOI: 10.2214/AJR.12.9049, ISSN: 1546-3141.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23436834.
  • Horn L, Keedy VL, Campbell N, Garcia G, Hayes A, Spencer B, Carbone DP, Sandler A, Johnson DH. Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. Clin Lung Cancer [print-electronic]. 2013 Jan; 14(1): 14-8. PMID: 22591607, PII: S1525-7304(12)00075-7, DOI: 10.1016/j.cllc.2012.03.008, ISSN: 1938-0690.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22591607.
  • Lovly CM, Horn L. Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC. Curr Treat Options Oncol. 2012 Dec; 13(4): 516-26. PMID: 22833206, DOI: 10.1007/s11864-012-0204-6, ISSN: 1534-6277.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22833206.
  • Horn L, Koehler E, Gilbert J, Johnson DH. Factors associated with the career choices of hematology and medical oncology fellows trained at academic institutions in the United States. J. Clin. Oncol [print-electronic]. 2011 Oct 10/10/2011; 29(29): 3932-8. PMID: 21911716, PMCID: PMC3189092, PII: JCO.2011.35.8663, DOI: 10.1200/JCO.2011.35.8663, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21911716.
  • Horn L, Zhao Z, Sandler A, Johnson D, Shyr Y, Wolff S, Devore RF, Laskin J. A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer. Clin Lung Cancer [print-electronic]. 2011 May; 12(3): 161-5. PMID: 21663858, PII: S1525-7304(11)00014-3, DOI: 10.1016/j.cllc.2011.03.013, ISSN: 1938-0690.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21663858.
  • Horn L, Castellanos EL, Johnson DH. Update on new drugs in small cell lung cancer. Expert Opin Investig Drugs. 2011 Apr; 20(4): 441-5. PMID: 21395484, DOI: 10.1517/13543784.2011.553185, ISSN: 1744-7658.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21395484.
  • Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, Schiller JH. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J. Clin. Oncol [print-electronic]. 2009 Dec 12/10/2009; 27(35): 6006-11. PMID: 19826110, PMCID: PMC2793043, PII: JCO.2009.23.7545, DOI: 10.1200/JCO.2009.23.7545, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19826110.
  • Horn L, Sandler A. Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin. Cancer Res [print-electronic]. 2009 Aug 8/15/2009; 15(16): 5040-8. PMID: 19671872, PMCID: PMC3528182, PII: 1078-0432.CCR-09-0520, DOI: 10.1158/1078-0432.CCR-09-0520, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19671872.
  • Horn L, Backlund M, Johnson DH. Targeting the eicosanoid pathway in non-small-cell lung cancer. Expert Opin. Ther. Targets [print-electronic]. 2009 Jun; 13(6): 675-88. PMID: 19409031, PMCID: PMC2891200, DOI: 10.1517/14728220902915567, ISSN: 1744-7631.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19409031.
  • Horn L, Sandler AB. Angiogenesis in the treatment of non-small cell lung cancer. Proc Am Thorac Soc. 2009 Apr 4/15/2009; 6(2): 206-17. PMID: 19349490, PII: 6/2/206, DOI: 10.1513/pats.200807-066LC, ISSN: 1546-3222.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19349490.
  • Horn L, Bernardo P, Sandler A, Wagner H, Levitan N, Levitt ML, Johnson DH. A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group. J Thorac Oncol. 2009 Apr; 4(4): 527-33. PMID: 19240650, PMCID: PMC3528175, DOI: 10.1097/JTO.0b013e31819c7daf, ISSN: 1556-1380.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19240650.
  • Horn L, Sandler AB. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. Clin Lung Cancer. 2009 Mar; 10 Suppl 1: S7-16. PMID: 19362948, PMCID: PMC3528174, PII: N68174866KG23867, DOI: 10.3816/CLC.2009.s.002, ISSN: 1525-7304.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19362948.
  • Horn L, Johnson DH. Evarts A. Graham and the first pneumonectomy for lung cancer. J. Clin. Oncol. 2008 Jul 7/1/2008; 26(19): 3268-75. PMID: 18591561, PII: 26/19/3268, DOI: 10.1200/JCO.2008.16.8260, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18591561.
  • Horn L, Tzanetos K, Thorpe K, Straus SE. Factors associated with the subspecialty choices of internal medicine residents in Canada. BMC Med Educ. 2008; 8: 37. PMID: 18582381, PMCID: PMC2446387, PII: 1472-6920-8-37, DOI: 10.1186/1472-6920-8-37, ISSN: 1472-6920.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18582381.